Investors Can Lead Securities Fraud Lawsuit Against Aardvark Therapeutics

Investors who have suffered losses in Aardvark Therapeutics, Inc. are now being called upon to lead a securities fraud class action lawsuit filed in the United States. The law firm Glancy Prongay Wolke & Rotter LLP announced that potential plaintiffs can seek to become the lead plaintiff before the October 13, 2026 deadline.

The lawsuit alleges that between February 2025 and May 2026, the company's management made materially false and misleading statements and failed to disclose adverse information about the company's business, operations, and prospects. Specifically, the safety and commercial outlook of the company's ARD-101 drug development project were allegedly overstated.

The litigation centers on claims that the company did not disclose to investors that the ARD-101 drug was less safe than represented. Consequently, the company's clinical, regulatory, and commercial prospects were overstated, leading to misleading public statements.

Glancy Prongay Wolke & Rotter LLP is urging investors wishing to serve as lead plaintiff to contact them by the deadline. The firm emphasizes that investors may retain counsel of their choice, and those who take no action will remain passive class members if the class action is not yet certified.